What is the value of anti-Müllerian hormone in predicting the response to ovarian stimulation with GnRH agonist and antagonist protocols?

Reproductive Biology and Endocrinology

Veljko Vlaisavljević¹  Maruška Medved¹  Borut Kovačič¹  Jure Knez¹ 

[1] Department of Reproductive Medicine and Gynaecologic Endocrinology, University Medical Centre Maribor, Ljubljanska 5, Maribor, 2000, Slovenia

关键词: GnRH agonist;    GnRH antagonist;    Poor response;    Excessive response;    Ovarian stimulation;    Anti-Müllerian hormone;   

Others  :  1216378
DOI  :  10.1186/s12958-015-0049-5

 received in 2015-03-01, accepted in 2015-05-21,  发布年份 2015

【 摘 要 】

Background

Anti-Müllerian hormone (AMH) is a marker of the ovarian reserve with promising prognostic potential in reproductive medicine. We aimed to evaluate the prognostic ability of AMH for predicting excessive or poor responses to ovarian stimulation using gonadotrophin-releasing hormone (GnRH) agonist and GnRH antagonist protocols in patients undergoing medically assisted reproduction (MAR) procedures.

Methods

This retrospective analysis included 623 women who underwent ovarian stimulation for medically assisted reproduction. AMH level measurements were acquired from all couples within six months of the initiation of ovarian stimulation.

Results

AMH was significantly correlated with the number of retrieved oocytes, and age was not relevant in a multivariate regression analysis (unstandardized regression coefficient of 1.130, 95 % confidence interval 0.977-1.283). AMH was a better predictor of both excessive (>19 oocytes) and poor (<4 oocytes) ovarian response than age (areas under the curve (AUCs) of 0.882 and 0.816, respectively). When stratified according to the stimulation protocol (a long GnRH agonist versus a GnRH antagonist protocol), AMH retained its high predictive value for excessive and poor responses in both groups. Serum AMH levels exhibited a strong correlation with the level of the response to ovarian stimulation.

Conclusions

AMH is an independent and an accurate predictor of excessive and poor responses to GnRH agonist and GnRH antagonist protocols for ovarian stimulation.

【 授权许可】

   
2015 Knez et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet. 1996; 348:1402-1406.
• [2]Te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002; 8:141-154.
• [3]Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006; 12:685-718.
• [4]Tarlatzis BC. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003; 9:61-76.
• [5]Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones. 2011; 10:95-103.
• [6]Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM et al.. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001; 142:4891-4899.
• [7]Durlinger ALL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW et al.. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002; 143:1076-1084.
• [8]Salmon NA, Handyside AH, Joyce IM. Oocyte regulation of anti-Müllerian hormone expression in granulosa cells during ovarian follicle development in mice. Dev Biol. 2004; 266:201-208.
• [9]Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91:941-945.
• [10]Pigny P. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88:5957-5962.
• [11]Laven JSE. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89:318-323.
• [12]Weenen C. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004; 10:77-83.
• [13]Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod. 2010; 25:1282-1287.
• [14]Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles–implications for individualization of therapy. Hum Reprod. 2007; 22:2414-2421.
• [15]Fanchin T. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003; 18:323-327.
• [16]La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P et al.. Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod. 2004; 19:2738-2741.
• [17]La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006; 21:3103-3107.
• [18]Van Disseldorp J, Lambalk CB, Kwee J, Looman CW, Eijkemans MJ, Fauser BC et al.. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010; 25:221-227.
• [19]Andersen AN, Witjes H, Gordon K, Mannaerts B. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod. 2011; 26:3413-3423.
• [20]Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS et al.. Anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction. Hum Reprod. 2010; 25:2597-2604.
• [21]Polyzos NP, Stoop D, Blockeel C, Adriaensen P, Platteau P, Anckaert E et al.. Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist-treated oocyte donors. Reprod Biomed Online. 2012; 24:532-539.
• [22]Arce J, La Marca A, Mirner Klein B, Nyboe Anderson A, Fleming R. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles : prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013; 99:1644-1653.
• [23]Polyzos NP, Nelson SM, Stoop D, Nwoye M, Humaidan P, Anckaert E et al.. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization – intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist ? A retrospective single-center study. Fertil Steril. 2013; 100:438-444.
• [24]Vlaisavljević V, Kovacic B, Gavrić-Lovrec V, Reljic M. Simplification of the clinical phase of IVF and ICSI treatment in programmed cycles. Int J Gynecol Obstet. 2000; 69:135-142.
• [25]Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P et al.. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009; 92:1586-1593.
• [26]La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC et al.. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010; 16:113-130.
• [27]Reljič M, Vlaisavljević V, Gavrić V, Kovačič B. Number of oocytes retrieved and resulting pregnancy. Risk factors for ovarian hyperstimulation syndrome. J Reprod Med. 1999; 44:714-718.
• [28]Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of “poor response” to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26:1616-1624.
• [29]Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002; 77:468-471.
• [30]Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M et al.. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009; 24:867-875.
• [31]Polyzos NP, Tournaye H, Guzman L, Camus M, Nelson SM. Predictors of ovarian response in women treated with corifollitropin alfa for in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2013; 100:430-437.
• [32]Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A et al.. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod. 2011; 26:2353-2362.
• [33]Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010; 94:389-400.
• [34]Kol S, Humaidan P. GnRH agonist triggering: recent developments. Reprod Biomed Online. 2013; 26:226-230.
• [35]Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011; 26:2593-2597.
• [36]Rombauts L, Onwude JL, Chew HW. The predictive value of antral follicle count remains unchanged across the menstrual cycle. Fertil Steril. 2011; 96:1514-1518.
• [37]Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril. 2010; 93:855-864.
• [38]La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S et al.. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007; 22:766-771.
• [39]Muttukrishna S, Mcgarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B : predictors of ovarian response in assisted reproductive technology? BJOG. 2005; 112:1384-1390.
• [40]Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006; 21:2022-2026.
• [41]Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online. 2011; 23:411-420.
• [42]Fréour T, Mirallié S, Bach-Ngohou K, Denis M, Barrière P, Masson D. Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta. 2007; 375:162-164.